澳门赌场招聘-赌场有哪些_免费百家乐追号软件_全讯网最新资讯网址 (中国)·官方网站

Medical Research

Nature Reviews Drug Discovery: targeting cancer-associated fibroblasts

Share
  • Updated: Dec 24, 2018
  • Written:
  • Edited:
Source: Sun Yat-sen Memorial Hospital
Written by: Xueman Chen
Edited by: Wang Dongmei

Recently, a Review Article entitled “Turning foes to friends: targeting cancer-associated fibroblasts” was published online in Nature Reviews Drug Discovery (IF 2018=50.17)1. Professor Erwei Song, President of Sun Yat-sen Memorial Hospital, Sun Yat-sen University, is the corresponding author, and Xueman Chen, a PhD student from his team, is the first author.

Current paradigms of cancer-centric therapeutics are usually not sufficient to eradicate the malignancy, as the cancer stroma may prompt tumor relapse and therapeutic resistance. In the past decade, a burst of knowledge on how the tumor microenvironment (TME) interacts with tumor cells has urged studies on a new cancer treatment paradigm: targeting the tumor stroma. Among all the stromal cells that populate the TME, cancer-associated fibroblasts (CAFs) are the most abundant and are critically involved in cancer progression, which render them as conspicuous stromal targets in many, if not all, solid tumors. However, without unequivocal cell-surface markers, live-cell sorting for functional and mechanistic studies on CAFs in vitro and targeting therapies towards CAFs in vivo are greatly hindered.

It is noteworthy that a previous research from Prof. Erwei Song’s team revealed CD10 and GPR77 as two specific cell-surface makers for a novel pro-tumorigenic CAF subset involved in cancer stemness and chemoresistance2. More importantly, GPR77 is a functional marker which can be directly targeted for in vivo CAF depletion. The restoration of chemosensitivity of tumor cells upon GPR77 blockade further suggests the remarkable therapeutic value of such a precise CAF-targeted strategy for cancers.


Accumulated molecular characterization of CAFs not only deepens our insights into their phenotypic heterogeneity and functional diversity, but also brings CAF-targeting therapies for cancer treatment onto the agenda. However, translating the basic research into clinical practice takes tremendous efforts and is extremely time-consuming, which makes it an urgent need for therapists and drug developers to comprehensively recognize the functional significance and molecular mechanisms of CAFs in cancers.

In this Review, Prof. Song’s team presented a full-scale overview regarding the current understanding of the hallmarks, biology and heterogeneity of CAFs, highlighting the CAF-centered intercellular crosstalk within the TME, and discussed multipronged functions of CAFs in tumor initiation, progression, metastasis and resistance to anticancer therapies. Prof. Song’s team also elaborated on the potential therapeutic strategies targeting CAFs, with an aim to accelerate the leap from bench to bedside.


References
1.  Chen, X. & Song, E. Turning foes to friends: targeting cancer-associated fibroblasts. Nature Reviews Drug Discovery (2018).
2.  Su, S., et al. CD10(+)GPR77(+) Cancer-Associated Fibroblasts Promote Cancer Formation and Chemoresistance by Sustaining Cancer Stemness. Cell (2018).

Link to the review article: www.nature.com/articles/s41573-018-0004-1
TOP
钻石国际| 澳门百家乐破解方法| Bet百家乐娱乐城| 皇冠网最新网址| 91百家乐的玩法技巧和规则| 三国百家乐官网的玩法技巧和规则| 威尼斯人娱乐cheng| 新澳博百家乐官网现金网| 中原百家乐的玩法技巧和规则| 太阳城百家乐官网网址-- | 台江县| 百家乐规则博彩正网| 七胜国际娱乐| 大发888全球顶级游戏平台| 太阳城棋牌| 大发888娱乐场 ylc8| 首席百家乐官网的玩法技巧和规则 | 百家乐官网方案| 娱乐城百家乐打不开| 宝胜娱乐| 百家乐娱乐平台代理佣金| 网络百家乐模拟投注| 百家乐官网玩法窍门| 财神百家乐娱乐城| 百家乐赌博详解| 百家乐官网网络游戏信誉怎么样| 金都百家乐的玩法技巧和规则| 百家乐官网小型抽水泵| 百家乐棋牌交友中心| 大发888代充值存款| 百家乐官网庄闲局部失| 百家乐官网资金注码| 百家乐官网视频游戏金币| 云鼎娱乐城| 百家乐是否能赢| 水果机遥控器多少钱| 琼海市| 金彩娱乐城| 大发888 迅雷快传| 瑞博网站| 宝都棋牌下载|